A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor
- Conditions
- HIV Infections
- Registration Number
- NCT00028067
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to compare the atazanavir and nelfinavir (NFV) treatments in their ability to reduce viral load.
- Detailed Description
In this double-blind, double-placebo, randomized, 2-arm study, atazanavir and NFV each are given in combination with 2 open-label nucleoside reverse transcriptase inhibitors (NRTIs) over 48 weeks. Patients assigned to atazanavir will receive placebo capsules which are identical in size and appearance to NFV. Patients assigned to NFV will receive placebo capsules which are identical in size and appearance to atazanavir. HIV levels are monitored.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 500
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (62)
Health for Life Clinic
🇺🇸Little Rock, Arkansas, United States
East Bay AIDS Ctr
🇺🇸Berkeley, California, United States
Orange County Ctr for Special Immunology
🇺🇸Fountain Valley, California, United States
Tower Infectious Diseases
🇺🇸Los Angeles, California, United States
Kaiser Hospital
🇺🇸Sacramento, California, United States
HIV Institute / Davies Med Ctr
🇺🇸San Francisco, California, United States
Kaiser Foundation Hospital
🇺🇸San Francisco, California, United States
IDC Research Initiative
🇺🇸Altamonte Springs, Florida, United States
Larry Bush
🇺🇸Atlantis, Florida, United States
Bach and Godofsky
🇺🇸Bradenton, Florida, United States
Scroll for more (52 remaining)Health for Life Clinic🇺🇸Little Rock, Arkansas, United States